Direct nose to brain delivery of small molecules: critical analysis of data from a standardized in vivo screening model in rats
- PMID: 33169635
- PMCID: PMC7655051
- DOI: 10.1080/10717544.2020.1837291
Direct nose to brain delivery of small molecules: critical analysis of data from a standardized in vivo screening model in rats
Abstract
The blood-brain barrier (BBB) is often a limiting factor for getting drugs in the brain. Bypassing the BBB by intranasal (IN), or also called nose to brain (NTB), route is an interesting and frequently investigated concept for brain drug delivery. However, despite the body of evidence for IN drug delivery in literature over the last decades, reproducibility and interpretation of animal data remain challenging. The objective of this project was to assess the feasibility and value of a standardized IN screening model in rats for the evaluation of direct brain delivery. A chemically diverse set of commercial and internal small molecules were tested in the in vivo model with different doses and/or formulations. Data were analyzed using different ways of ratio calculations: blood concentration at time of sacrifice, total exposure in blood (area under the curve, AUC) and the brain or olfactory bulb concentrations. The IN route was compared to another parenteral route to decide if there is potential direct brain transport. The results show that blood and tissue concentrations and ratios are highly variable and not always reproducible. Potential direct brain delivery was concluded for some compounds, however, sometimes depending on the analysis: using blood levels at sacrifice or AUC could lead to different conclusions. We conclude that a screening model for the evaluation of direct brain transport of small molecules is very difficult to achieve and a conclusion based on a limited number of animals with this variability is questionable.
Keywords: Drug delivery; brain targeting; direct CNS transport; intranasal; nose to brain; rat.
Conflict of interest statement
The authors declare to have no conflict of interest relevant to this article.
Figures


Similar articles
-
Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting.Expert Opin Drug Deliv. 2013 Jul;10(7):957-72. doi: 10.1517/17425247.2013.790887. Epub 2013 Apr 16. Expert Opin Drug Deliv. 2013. PMID: 23586809 Review.
-
Recent patents review on intranasal administration for CNS drug delivery.Recent Pat Drug Deliv Formul. 2008;2(1):25-40. doi: 10.2174/187221108783331429. Recent Pat Drug Deliv Formul. 2008. PMID: 19075895 Review.
-
Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting.Drug Deliv. 2014 Mar;21(2):148-54. doi: 10.3109/10717544.2013.838014. Epub 2013 Oct 16. Drug Deliv. 2014. PMID: 24128122
-
Can nasal drug delivery bypass the blood-brain barrier?: questioning the direct transport theory.Drugs R D. 2007;8(3):133-44. doi: 10.2165/00126839-200708030-00001. Drugs R D. 2007. PMID: 17472409 Review.
-
From nose to brain: understanding transport capacity and transport rate of drugs.Expert Opin Drug Deliv. 2008 Oct;5(10):1159-68. doi: 10.1517/17425247.5.10.1159. Expert Opin Drug Deliv. 2008. PMID: 18817519 Review.
Cited by
-
Mefenamic Acid Loaded and TPGS Stabilized Mucoadhesive Nanoemulsion for the Treatment of Alzheimer's Disease: Development, Optimization, and Brain-Targeted Delivery via Olfactory Pathway.AAPS PharmSciTech. 2024 Jan 10;25(1):16. doi: 10.1208/s12249-023-02727-0. AAPS PharmSciTech. 2024. PMID: 38200387
-
Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration.Pharm Res. 2023 May;40(5):1087-1114. doi: 10.1007/s11095-023-03469-1. Epub 2023 Jan 12. Pharm Res. 2023. PMID: 36635488 Free PMC article. Review.
-
The Nasal-Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases.MedComm (2020). 2025 Jun 6;6(6):e70213. doi: 10.1002/mco2.70213. eCollection 2025 Jun. MedComm (2020). 2025. PMID: 40487748 Free PMC article. Review.
-
Cathepsin B inhibition blocks amyloidogenesis in the mouse models of neurological lysosomal diseases MPS IIIC and sialidosis.Mol Ther Methods Clin Dev. 2025 Feb 11;33(1):101432. doi: 10.1016/j.omtm.2025.101432. eCollection 2025 Mar 13. Mol Ther Methods Clin Dev. 2025. PMID: 40092638 Free PMC article.
-
Effects of Intranasal Naloxone on Hypoglycemia-associated Autonomic Failure in Susceptible Individuals.J Clin Endocrinol Metab. 2025 Jan 21;110(2):462-470. doi: 10.1210/clinem/dgae479. J Clin Endocrinol Metab. 2025. PMID: 39026458 Free PMC article. Clinical Trial.
References
-
- Bagger M, Bechgaard E. (2004). A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. Int J Pharm 269:311–22. - PubMed
-
- Bailey A, Baum R, Horn K, et al. (2017). Review of intranasally administered medications for use in the emergency department. J Emerg Med 53:38–48. - PubMed
-
- Balin BJ, Broadwell RD, Salcman M, el-Kalliny M. (1986). Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol 251:260–80. - PubMed
-
- Crowe T, Greenlee M, Kanthasamy A, Hsu W. (2018). Mechanism of intranasal drug delivery directly to the brain. Life Sci 195:44–52. - PubMed
-
- Dhuria S, Hanson L, Frey W. (2010). Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99:1654–73. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources